Table 1.
Clinicopathological data of the included patients
| Characteristics | Number of patients (%) | |
|---|---|---|
| All patients |
|
85 (100) |
| Age |
Median (range) |
64 (26–76) |
| HER2 |
Positive |
17 (20) |
| |
Negative |
68 (80) |
| Ki67 |
≤ 20% |
54 (74) |
| |
> 20% |
19 (26) |
| ER status |
Positive |
62 (73) |
| |
Negative |
23 (27) |
| Pr status |
Positive |
41 (48) |
| |
Negative |
44 (52) |
| Histology |
Ductal |
67 (81) |
| |
Lobular |
10 (12) |
| |
Ductal + Lobular |
4 (5) |
| |
Other |
2 (2) |
| |
Missing |
2 |
| Tumor size |
≤ 20% |
25 (29) |
| |
> 20% |
60 (71) |
| Grade |
1 |
2 (3) |
| |
2 |
36 (60) |
| |
3 |
22 (37) |
| |
Missing |
25 |
| Nodal status |
N1 |
22 (26) |
| |
N2-3 |
25 (29) |
| |
N4+ |
38 (45) |
| Events1 |
Yes |
25 (29) |
| No | 60 (71) | |
Abbreviations: ER oestrogen receptor, PR progesteron receptor, HER2 human epidermal growth factor receptor 2, Grade Nottingham histological grade.
1Events: recurrence and/or death in breast cancer disease.